Russo Mark W, Steuerwald Nury, Norton Harry J, Anderson William E, Foureau David, Chalasani Naga, Fontana Robert J, Watkins Paul B, Serrano Jose, Bonkovsky Herbert L
Carolinas Healthcare System, Charlotte, NC, USA.
Indiana University School of Medicine, Indianapolis, IN, USA.
Liver Int. 2017 May;37(5):757-764. doi: 10.1111/liv.13312. Epub 2016 Nov 29.
BACKGROUND & AIMS: Drug induced liver injury (DILI) is challenging because of the lack of biomarkers to predict mortality. Our aim was to describe miRNA changes in sera of subjects with acute idiosyncratic DILI and determine if levels of miRNAs were associated with 6 month mortality. METHODS: Clinical data and sera were collected from subjects enrolled in the Drug Induced Liver Injury Network prospective study. miRNAs were isolated from serum obtained from 78 subjects within 2 weeks of acute DILI and followed up for 6 months or longer. miRNAs were compared to 40 normal controls and 6 month survivors vs non-survivors. RESULTS: The mean age of the DILI cohort was 48 years, and 55% were female. Eleven (14.1%) subjects died, 10 within 6 months of DILI onset, 5 (45%) liver related. Lower levels of miRNAs-122, -4463 and -4270 were associated with death within 6 months (P<.05). None of the subjects with miRNA-122 greater than the median value died within 6 months for a sensitivity of 100% and specificity of 57%. In subjects with a serum albumin <2.8 g/dL and miR-122<7.89 RFU the sensitivity, specificity, positive and negative predictive values for death within 6 months were 100%, 57%, 38% and 100% respectively. CONCLUSIONS: Serum miRNA-122 combined with albumin accurately identified subjects who died within 6 months of drug induced liver injury. If confirmed prospectively, miRNA-122 and albumin may be useful in identifying patients at high risk for mortality or liver transplantation.
背景与目的:由于缺乏预测死亡率的生物标志物,药物性肝损伤(DILI)具有挑战性。我们的目的是描述急性特异质性DILI患者血清中的miRNA变化,并确定miRNA水平是否与6个月死亡率相关。 方法:从药物性肝损伤网络前瞻性研究中纳入的受试者收集临床数据和血清。在急性DILI发病2周内从78名受试者获得的血清中分离miRNA,并随访6个月或更长时间。将miRNA与40名正常对照以及6个月存活者与非存活者进行比较。 结果:DILI队列的平均年龄为48岁,55%为女性。11名(14.1%)受试者死亡,10名在DILI发病后6个月内死亡,5名(45%)与肝脏相关。miRNA-122、-4463和-4270水平较低与6个月内死亡相关(P<0.05)。miRNA-122大于中位数的受试者在6个月内均未死亡,敏感性为100%,特异性为57%。在血清白蛋白<2.8g/dL且miR-122<7.89 RFU的受试者中,6个月内死亡的敏感性、特异性、阳性和阴性预测值分别为100%、57%、38%和100%。 结论:血清miRNA-122与白蛋白相结合可准确识别药物性肝损伤6个月内死亡的受试者。如果前瞻性研究得到证实,miRNA-122和白蛋白可能有助于识别有高死亡率或肝移植风险的患者。
J Gastroenterol Hepatol. 2013-1
Int J Mol Sci. 2022-5-27
Acta Pharm Sin B. 2021-12
World J Gastroenterol. 2021-11-21
Expert Opin Drug Metab Toxicol. 2021-11
Arch Toxicol. 2021-11
Cell. 2015-3-12
Semin Liver Dis. 2015-2
Hum Fertil (Camb). 2015-3
Gastroenterology. 2014-7
Expert Rev Clin Pharmacol. 2014-4-2
PLoS One. 2014-2-26
Biomark Med. 2014